WHG
CRNX icon

Westwood Holdings Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Westwood Holdings Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-28,402
Closed -$456K – 495
2023
Q1 		$456K Buy
28,402
+3,031
+12% +$56.1K ﹤0.01% 410
2022
Q4 		$464K Buy
25,371
+4,329
+21% +$76.3K ﹤0.01% 417
2022
Q3 		$413K Buy
+21,042
New +$429K ﹤0.01% 390

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Westwood Holdings Group's CRNX Position: Q2 2023 in Review

Westwood Holdings Group sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2023, closing a stake of 28,402 shares — an estimated $456K sold.

Westwood Holdings Group first reported a position in CRNX in Q3 2022 and held it in 3 quarters. The position peaked at $464K in Q4 2022. 140 funds tracked by Wall St. Rank hold CRNX as of Q2 2023.

  • Westwood Holdings Group reported no remaining Crinetics Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Westwood Holdings Group sold 28,402 Crinetics Pharmaceuticals shares in Q2 2023, an estimated $456K.
  • Westwood Holdings Group first reported a position in Crinetics Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Westwood Holdings Group's Crinetics Pharmaceuticals position peaked at $464K in Q4 2022.
  • 140 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2023.

Based on Westwood Holdings Group's 13F filing for Q2 2023, filed 11 Aug 2023.